Larimar Therapeutics, Inc.(LRMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LRMR Larimar Therapeutics, Inc.

Post-Mkt 01-16 18:34:54 EST

3.13

-0.13

-3.99%

盘后3.20

+0.07+2.24%

18:10 EST

High3.39	Low3.09	Vol1.62M
Open3.27	D1 Closing3.26	Amplitude9.36%
Mkt Cap267.90M	Tradable Cap141.32M	Total Shares85.59M
T/O5.14M	T/O Rate3.58%	Tradable Shares45.15M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LRMR","market":"US","secType":"STK","nameCN":"Larimar Therapeutics, Inc.","latestPrice":3.13,"timestamp":1768597200000,"preClose":3.26,"halted":0,"volume":1617077,"hourTrading":{"tag":"盘后","latestPrice":3.2,"preClose":3.13,"latestTime":"18:10 EST","volume":38019,"amount":121092.16122269999,"timestamp":1768605007582},"delay":0,"floatShares":45149399,"shares":85590400,"eps":-1.953372,"marketStatus":"Post-Mkt","change":-0.13,"latestTime":"01-16 18:34:54 EST","open":3.27,"high":3.39,"low":3.085,"amount":5136318.6026537,"amplitude":0.093558,"askPrice":3.45,"askSize":100,"bidPrice":3.12,"bidSize":40,"shortable":3,"etf":0,"ttmEps":-1.953372,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1768611600000},"marketStatusCode":4,"adr":0,"listingDate":1403150400000,"exchange":"NASDAQ","adjPreClose":3.26,"postHourTrading":{"tag":"盘后","latestPrice":3.2,"preClose":3.13,"latestTime":"18:10 EST","volume":38019,"amount":121092.16122269999,"timestamp":1768605007582},"volumeRatio":1.387852,"impliedVol":2.5378,"impliedVolPercentile":0.7649},"requestUrl":"/m/hq/s/LRMR/wiki","defaultTab":"wiki","newsList":[{"id":"2592990919","title":"Larimar Therapeutics Swaps Common Shares for Series A Convertible Preferred Stock in Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2592990919","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592990919?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:01","pubTimestamp":1765976508,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics Inc. announced that it has entered into an exchange agreement with Blue Owl Healthcare Opportunities IV Public Investments LP. Under the agreement, Blue Owl exchanged 2,500,000 shares of Larimar's common stock for 250,000 shares of newly designated Series A convertible preferred stock. The preferred stock, described as \"toothless,\" is convertible into common stock at a ratio of 1-to-10, subject to certain ownership limits. The transaction was completed as an unregistered sale, relying on the exemption from registration provided by Section 3 of the Securities Act.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Larimar Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the El","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL3fZs94:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BBT3K403.USD","LRMR","IE00BLSP4452.SGD","BK4135","IE00BLSP4239.USD","BK4139","OWL","IE00BN8TJ469.HKD"],"gpt_icon":0},{"id":"2584926815","title":"Larimar Therapeutics Q3 Net Income USD -47.712 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584926815","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584926815?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:38","pubTimestamp":1763570317,"startTime":"0","endTime":"0","summary":"Nov 05 (Reuters) - Larimar Therapeutics Q3 operating expenses USD 49.499 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 05-NOV-202512:00:50.457 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD9Y0qxd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LRMR","BK4139"],"gpt_icon":0},{"id":"2581095673","title":"Analysts Offer Insights on Healthcare Companies: Radnet (RDNT), Palvella Therapeutics (PVLA) and Larimar Therapeutics (LRMR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581095673","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581095673?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:10","pubTimestamp":1762434619,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Radnet (RDNT – Research Report), Palvella Therapeuti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-radnet-rdnt-palvella-therapeutics-pvla-and-larimar-therapeutics-lrmr-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-radnet-rdnt-palvella-therapeutics-pvla-and-larimar-therapeutics-lrmr-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","LU0128526141.USD","XLV","RDNT","BK4137","BK4581","XBI","LU2065731478.USD","BK4139","BK4196","BK4588","LABU","LU0029874061.USD","PVLA","BK4585","LRMR"],"gpt_icon":0},{"id":"2581243717","title":"Larimar Therapeutics Q3 net loss widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2581243717","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581243717?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:17","pubTimestamp":1762345076,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics Q3 net loss widensOverviewLarimar reports Q3 net loss of $47.7 mln, driven by increased R&D expensesCompany modifies nomlabofusp dosing to reduce anaphylaxis riskBLA submission fo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL1N3WH0KW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LRMR"],"gpt_icon":0},{"id":"2581721810","title":"BRIEF-Larimar Therapeutics Q3 Net Income USD -47.712 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581721810","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581721810?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:00","pubTimestamp":1762344050,"startTime":"0","endTime":"0","summary":"BRIEF-Larimar Therapeutics Q3 Net Income USD -47.712 Million\n\n\nNov 05 (Reuters) - Larimar Therapeutics Q3 operating expenses USD 49.499 million.\n\nQ3 basic EPS USD -0.61\nQ3 income from operations USD -49.499 million\nQ3 EPS USD -0.61","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nPLX4E8E5E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LRMR","BK4139"],"gpt_icon":0},{"id":"2581777729","title":"Larimar Therapeutics Q3 Basic EPS USD -0.61","url":"https://stock-news.laohu8.com/highlight/detail?id=2581777729","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581777729?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:00","pubTimestamp":1762344004,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nPLX4E8E5E:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LRMR","BK4139"],"gpt_icon":0},{"id":"2581724964","title":"Larimar Therapeutics Inc - Targets Bla Submission for Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2581724964","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581724964?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:00","pubTimestamp":1762344004,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nPLX4E8E5E:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LRMR","BK4139"],"gpt_icon":0},{"id":"2577515077","title":"Larimar Therapeutics Inc  expected to post a loss of 40 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2577515077","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577515077?lang=en_us&edition=fundamental","pubTime":"2025-10-24 20:22","pubTimestamp":1761308525,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics Inc  expected to post a loss of40cents a share - Earnings Preview Larimar Therapeutics Inc LRMR.OQ LRMR.O is expected to  show no change in quarterly revenue when it reports  resu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nL8N3W518F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LRMR"],"gpt_icon":0},{"id":"2573940067","title":"Truist Financial Sticks to Its Buy Rating for Larimar Therapeutics (LRMR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2573940067","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573940067?lang=en_us&edition=fundamental","pubTime":"2025-10-08 19:36","pubTimestamp":1759923401,"startTime":"0","endTime":"0","summary":"Truist Financial analyst Joon Lee maintained a Buy rating on Larimar Therapeutics today. The company’s shares closed yesterday at $4.72. Lee covers...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-sticks-to-its-buy-rating-for-larimar-therapeutics-lrmr-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-sticks-to-its-buy-rating-for-larimar-therapeutics-lrmr-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LRMR"],"gpt_icon":0},{"id":"2572637585","title":"Do Positive Friedreich's Ataxia Study Results Shift Larimar Therapeutics’ (LRMR) Long-Term Value Proposition?","url":"https://stock-news.laohu8.com/highlight/detail?id=2572637585","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572637585?lang=en_us&edition=fundamental","pubTime":"2025-10-04 05:55","pubTimestamp":1759528545,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics recently announced positive data from its long-term open-label study evaluating daily subcutaneous injections of nomlabofusp in patients with Friedreich's Ataxia, alongside an update on its development program.\nThis milestone highlights progress in advancing novel treatments for a rare neurological disease, capturing interest among rare disease and biotech stakeholders.\nWe’ll explore how the encouraging clinical results for nomlabofusp are influencing Larimar...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lrmr/larimar-therapeutics/news/do-positive-friedreichs-ataxia-study-results-shift-larimar-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lrmr/larimar-therapeutics/news/do-positive-friedreichs-ataxia-study-results-shift-larimar-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LRMR","BK4139"],"gpt_icon":0},{"id":"2572512595","title":"Larimar Therapeutics : Oppenheimer Cuts Target Price to $21 From $26","url":"https://stock-news.laohu8.com/highlight/detail?id=2572512595","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572512595?lang=en_us&edition=fundamental","pubTime":"2025-10-02 20:25","pubTimestamp":1759407904,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251002:nAZN4LSBVQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LRMR","BK4139"],"gpt_icon":0},{"id":"2571349298","title":"Analysts Are Bullish on Top Healthcare Stocks: Larimar Therapeutics (LRMR), Inventiva (IVA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2571349298","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571349298?lang=en_us&edition=fundamental","pubTime":"2025-09-30 19:00","pubTimestamp":1759230012,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Larimar Therapeutics (LRMR – Research Report) and In...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-larimar-therapeutics-lrmr-inventiva-iva-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-larimar-therapeutics-lrmr-inventiva-iva-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4137","BK4139","XBI","BK4585","IVA","LABU","BK4112","LRMR","HCSG","XLV","BK4581"],"gpt_icon":0},{"id":"2571811316","title":"U.S. RESEARCH ROUNDUP-Electronic Arts, Kala Bio, Semtech","url":"https://stock-news.laohu8.com/highlight/detail?id=2571811316","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571811316?lang=en_us&edition=fundamental","pubTime":"2025-09-30 15:01","pubTimestamp":1759215714,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Electronic Arts, Kala Bio, SemtechSept 30 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Electron","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nL3N3VH0GG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MATX","LU0170899867.USD","PSTL","SMTC","IE00BLSP4452.SGD","TSYW.SI","COLD","ACHC","ETSY","NUVB","TMUS","BK4139","BK4548","SG9999018857.SGD","ASO","PRGS","IMVT","CSX","LU1548497426.USD","SN","BK4171","CC","KALA","WMB","IE00B3T34201.USD","LU2896262040.SGD","CCL.UK","EA","FTAI","LU0689472784.USD","TAP","BK4598","LU0208291251.USD","IE0034235303.USD","IE00BMPRXN33.USD","MTN","LRMR","STZ","LU2552382058.USD","BK4543","SAM","UBER","CUZ","LU0943347566.SGD","CCL","LU1983260115.SGD","LYFT"],"gpt_icon":1},{"id":"2571108362","title":"Larimar Therapeutics (LRMR) Gets a Buy from JonesTrading","url":"https://stock-news.laohu8.com/highlight/detail?id=2571108362","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571108362?lang=en_us&edition=fundamental","pubTime":"2025-09-30 08:15","pubTimestamp":1759191311,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Catherine Novack from JonesTrading maintained a Buy rating on Larimar Therapeutics, with a price target of $7.00. T...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/larimar-therapeutics-lrmr-gets-a-buy-from-jonestrading-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/larimar-therapeutics-lrmr-gets-a-buy-from-jonestrading-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LRMR"],"gpt_icon":0},{"id":"2571464364","title":"Leerink Partners Keeps Their Buy Rating on Larimar Therapeutics (LRMR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2571464364","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571464364?lang=en_us&edition=fundamental","pubTime":"2025-09-30 07:45","pubTimestamp":1759189510,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Joori Park reiterated a Buy rating on Larimar Therapeutics today and set a price target of $25.00. The company’s shares cl...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/leerink-partners-keeps-their-buy-rating-on-larimar-therapeutics-lrmr-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/leerink-partners-keeps-their-buy-rating-on-larimar-therapeutics-lrmr-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LRMR"],"gpt_icon":0},{"id":"2571351154","title":"Larimar Therapeutics Down Nearly 29%, on Pace for Largest Percent Decrease Since May 2023 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2571351154","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571351154?lang=en_us&edition=fundamental","pubTime":"2025-09-30 02:05","pubTimestamp":1759169100,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics, Inc.  is currently at $3.62, down $1.47 or 28.85%. --On pace for largest percent decrease since May 15, 2023, when it fell 29.05%. --Down 99.41% from its all-time closing high of $616.08 on March 19, 2015. --Down 44.66% from 52 weeks ago , when it closed at $6.55. --Up 111.99% from its 52-week closing low of $1.71 on April 8, 2025. --Traded as low as $3.10; lowest intraday level since July 7, 2025, when it hit $3.01. --Down 39.16% at today's intraday low; largest intraday percent decrease since Dec. 16, 2024, when it fell as much as 51.22%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LRMR","LENZ","BK4539","BK4007","BK4139"],"gpt_icon":0},{"id":"2571358366","title":"Larimar Therapeutics Stock Falls After Patients Report Allergic Reaction In Pivotal Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2571358366","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571358366?lang=en_us&edition=fundamental","pubTime":"2025-09-29 23:20","pubTimestamp":1759159200,"startTime":"0","endTime":"0","summary":"Larimar Therapeutics Inc. (NASDAQ: LRMR) is trading lower on Monday after the company released data from the ongoing long-term open-label (OL) study evaluating daily subcutaneous 25 mg and 50 mg injections of nomlabofusp self-administered or administered by a caregiver in participants with","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/09/29/Scientific-research.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/09/29/Scientific-research.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/09/47920098/larimar-therapeutics-stock-falls-after-patients-report-allergic-reaction-in-pivotal-study","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/09/47920098/larimar-therapeutics-stock-falls-after-patients-report-allergic-reaction-in-pivotal-study","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4539","LU1169589451.USD","LU1169590202.USD","LRMR","BK4007","BK4535","PD","LENZ","PK","FA","BK4023","BK4130","BK4218","BK4181","BK4139"],"gpt_icon":0},{"id":"2571362183","title":"BUZZ-Larimar Therapeutics tumbles on safety concerns over rare genetic disorder drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2571362183","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571362183?lang=en_us&edition=fundamental","pubTime":"2025-09-29 21:01","pubTimestamp":1759150890,"startTime":"0","endTime":"0","summary":"BUZZ-Larimar Therapeutics tumbles on safety concerns over rare genetic disorder drug** Shares of Larimar Therapeutics LRMR.O fall 31% to $3.50 premarket on safety concerns about its experimental drug, nomlabofusp, after data from a long-term study** Drug was being tested for Friedreich's ataxia, a rare genetic disorder that causes progressive damage to the nervous system** Seven participants experienced anaphylaxis within the first 6 weeks of dosing and were withdrawn from the study, co says** Anaphylaxis is a sudden and severe allergic reaction that can cause breathing problems, swelling and a drop in blood pressure** \"The major downside is that we continue to see anaphylaxis\" - Jones Trading analyst Catherine Novack** As of last close, stock up 31% YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nL3N3VG0U5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LRMR"],"gpt_icon":0},{"id":"2571387438","title":"BRIEF-Larimar Reports Positive Long-Term Data, Updates Nomlabofusp Program for Friedreich’s Ataxia","url":"https://stock-news.laohu8.com/highlight/detail?id=2571387438","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571387438?lang=en_us&edition=fundamental","pubTime":"2025-09-29 19:19","pubTimestamp":1759144746,"startTime":"0","endTime":"0","summary":"BRIEF-Larimar Reports Positive Long-Term Data, Updates Nomlabofusp Program for Friedreich’s AtaxiaSept 29 (Reuters) - Larimar Therapeutics Inc LRMR.O:LARIMAR THERAPEUTICS ANNOUNCES POSITIVE DATA FROM ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nTUAMH4DL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LRMR","BK4139"],"gpt_icon":1},{"id":"2571387908","title":"Larimar Therapeutics Shares Drop 52% Premarket After Co Reports Long-Term Late-Stage Data for Genetic Disorder Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2571387908","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571387908?lang=en_us&edition=fundamental","pubTime":"2025-09-29 19:15","pubTimestamp":1759144543,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nL3N3VG0MO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LRMR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.larimartx.com","stockEarnings":[{"period":"1week","weight":-0.0298},{"period":"1month","weight":-0.1283},{"period":"3month","weight":-0.2238},{"period":"6month","weight":0.0156},{"period":"1year","weight":-0.0412},{"period":"ytd","weight":-0.1444}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0419},{"period":"6month","weight":0.103},{"period":"1year","weight":0.1678},{"period":"ytd","weight":0.0151}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.583333,"avgChangeRate":0.081911},{"month":2,"riseRate":0.545455,"avgChangeRate":0.052852},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.145103},{"month":4,"riseRate":0.363636,"avgChangeRate":-0.028256},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.091938},{"month":6,"riseRate":0.545455,"avgChangeRate":0.006336},{"month":7,"riseRate":0.5,"avgChangeRate":-0.021968},{"month":8,"riseRate":0.5,"avgChangeRate":0.081374},{"month":9,"riseRate":0.416667,"avgChangeRate":0.000938},{"month":10,"riseRate":0.666667,"avgChangeRate":-0.029427},{"month":11,"riseRate":0.583333,"avgChangeRate":0.038429},{"month":12,"riseRate":0.583333,"avgChangeRate":0.050649}],"exchange":"NASDAQ","name":"Larimar Therapeutics, Inc.","nameEN":"Larimar Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Larimar Therapeutics, Inc.(LRMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Larimar Therapeutics, Inc.(LRMR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Larimar Therapeutics, Inc.,LRMR,Larimar Therapeutics, Inc.股票,Larimar Therapeutics, Inc.股票老虎,Larimar Therapeutics, Inc.股票老虎国际,Larimar Therapeutics, Inc.行情,Larimar Therapeutics, Inc.股票行情,Larimar Therapeutics, Inc.股价,Larimar Therapeutics, Inc.股市,Larimar Therapeutics, Inc.股票价格,Larimar Therapeutics, Inc.股票交易,Larimar Therapeutics, Inc.股票购买,Larimar Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Larimar Therapeutics, Inc.(LRMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Larimar Therapeutics, Inc.(LRMR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction